In this article, Sarah Ray, Senior Research Analyst, explores the following issue: amidst a regulatory environment which increasingly focuses on evidence-based research, many life science teams have turned their attentions to health outcomes and comparative effectiveness research. However, while useful assessments in their own right, these tools may not yield considerable insight into the patient perspective. Instead, companies may need to implement additional patient-focused strategies to gauge how emerging products will align with patients’ current treatment regimens.